Response to Comments: MolDX: Plasma-Based Genomic Profiling in Solid Tumors

This document is a response-to-comments for the MolDX Plasma-Based Genomic Profiling Local Coverage Determination (L39230), noting the public comment period (2022-01-20 to 2022-03-05), notice period start (2022-11-10), and LCD effective date (2022-12-26). It emphasizes that peer-reviewed evidence is given greater weight in policy decisions and that MACs may consolidate or redact comments; this document does not itself state clinical coverage criteria.

"Public comment period for MolDX L39230 was open from 2022-01-20 through 2022-03-05; notice period begins 2022-11-10 and the LCD becomes effective 2022-12-26."

Sign up to see full coverage criteria, indications, and limitations.